Aandelen in “Productie van biologische producten”

Aandeel Datum Koers Evolutie
vlag Adaptive Biotechnologies Corp 14/04 14,530 USD
+2,83% 		+2,83%
vlag Adma Biologics Inc 14/04 10,490 USD
+1,06% 		+1,06%
vlag Agenus Inc 14/04 4,720 USD
+13,73% 		+13,73%
vlag Alector Inc 14/04 2,410 USD
+3,43% 		+3,43%
vlag Amgen 14/04 350,950 USD
+0,32% 		+0,32%
vlag ANI Pharmaceuticals Inc 14/04 78,290 USD
-0,03% 		-0,03%
vlag Aptose Biosciences Inc 14/04 2,340 CAD
-0,43% 		-0,43%
vlag argenx 14/04 828,350 USD
+2,36% 		+2,36%
vlag argenx 14/04 705,000 EUR
+4,14% 		+4,14%
vlag Armata Pharmaceuticals Inc 14/04 12,880 USD
+10,18% 		+10,18%
vlag Atara Biotherapeutics Inc 14/04 5,150 USD
+5,32% 		+5,32%
vlag Autolus Therapeutics plc 13/04 1,470 USD
-1,34% 		-1,34%

Nieuws over “Productie van biologische producten”

14/04 · Neurocrine Biosciences Presents First Real-World Head-to-Head Claims Analysis Demonstrating Greater Treatment Persistence with INGREZZA® (valbenazine) Capsules Compared to AUSTEDO XR · Persbericht

14/04 · Neurocrine Biosciences Presents First Real-World Head-to-Head Claims Analysis Demonstrating Greater Treatment Persistence with INGREZZA® (valbenazine) Capsules Compared to AUSTEDO XR · Persbericht

14/04 · Bio-Techne to Host Conference Call on May 6, 2026, to Announce Third Quarter Fiscal 2026 Financial Results · Persbericht

13/04 · Cema-Cel Pivotal Trial Interim Data Highlight Strength of Cellectis’ Allogeneic CAR-T Platform · Persbericht

13/04 · Daraxonrasib Demonstrates Unprecedented Overall Survival Benefit in Pivotal Phase 3 RASolute 302 Clinical Trial in Patients with Metastatic Pancreatic Cancer · Persbericht

10/04 · Atara Biotherapeutics, Inc. (ATRA) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit · Persbericht

10/04 · RGNX UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds REGENXBIO (RGNX) Investors of Securities Class Action Deadline on April 14, 2026 · Persbericht

10/04 · ATRA UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Atara Biotherapeutics (ATRA) Investors of Securities Class Action Deadline on May 22, 2026 · Persbericht

9/04 · Pomerantz Law Firm Announces the Filing of a Class Action Against Atara Biotherapeutics, Inc. and Certain Officers - ATRA · Persbericht

7/04 · Monthly information on share capital and company voting rights · Persbericht

7/04 · GENFIT Announces Publication of the 2025 Universal Registration Document   · Persbericht

7/04 · Belgen cashen 125 miljoen dollar op miljardenovername van Duits biotechbedrijf · Tijd.be (€)

Het Belgische biotechfonds Fund+ strijkt als vroege investeerder minstens 125 miljoen dollar op bij de verkoop van het Duitse biotechbedrijf Tubulis aan de Amerikaanse farmareus Gilead.

7/04 · Halozyme Announces Global Collaboration and License Agreement with Vertex Pharmaceuticals for Hypercon™ Technology · Persbericht

6/04 · Greenberg Traurig Represents Israel-based Entera Bio in $10M Private Placement Led by BVF Partners · Persbericht

6/04 · AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR SUBCUTANEOUS TEPEZZA® IN ADULTS LIVING WITH MODERATE-TO-SEVERE ACTIVE THYROID EYE DISEASE · Persbericht

6/04 · Neurocrine to Acquire Soleno Therapeutics, Expanding Its Endocrinology and Rare Disease Portfolio · Persbericht

3/04 · REGENXBIO, Inc. Class Action Reminder - Robbins LLP Encourages RGNX Stockholders to Contact the Firm for Information About Their Rights · Persbericht

3/04 · ATRA INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Atara Biotherapeutics (ATRA) Investors of Securities Class Action Deadline on May 22, 2026 · Persbericht

2/04 · Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of March 31, 2026 · Persbericht

2/04 · GENFIT Reports Full-Year 2025 Financial Results and Provides Corporate Update   · Persbericht

2/04 · Pomerantz Law Firm Announces the Filing of a Class Action Against Atara Biotherapeutics, Inc. and Certain Officers - ATRA · Persbericht

Mijn selecties